Cancer-Associated Venous Thromboembolism—Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline

Hanno Riess; Jan Beyer-Westendorf; Uwe Pelzer; Robert Klamroth; Birgit Linnemann

doi:10.1055/a-2178-6508

Hämostaseologie, Table of Contents

Hamostaseologie 2024; 44(02): 143-149
DOI: 10.1055/a-2178-6508

Review Article

Cancer-Associated Venous Thromboembolism—Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline

Diagnostik und Therapie der Malignom-assoziierten venösen Thromboembolie

Hanno Riess

¹Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

,

Jan Beyer-Westendorf

²Department of Hematology, Medical Faculty, University Hospital Carl Gustav-Carus, Dresden, Germany

,

Uwe Pelzer

¹Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

,

Robert Klamroth

³Department of Internal Medicine and Vascular Medicine, Vivantes Hospital in Friedrichshain, Berlin, Germany

,

Birgit Linnemann

⁴Cardiology III – Angiology, Department of Cardiology, University Hospital of the Johannes-Gutenberg University, Mainz, Germany

› Author Affiliations

Abstract

Patients with cancer are prone to develop venous thromboembolism (VTE) with negative impact on quality of life, morbidity, and mortality. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE (CAT) basically comprises initial and maintenance treatment, for 3 to 6 months, secondary preventions, and treatment in special situations. Therapeutic anticoagulation is the treatment of choice in CAT. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that had been recommended for decades, direct oral anti-factor Xa inhibitors, a subgroup of direct oral anticoagulants (DOACs), demonstrated their advantages along with the accompanying concerns in several randomized controlled treatment trials of CAT. The latest guidelines, such as the German AWMF-S2k Guideline “Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism,” agree with each other on most aspects with respect to the treatment of CAT. Encompassing recent clinical studies, and meta-analyses, as well as the focus on some special management aspects of CAT, the objective of this review is to present a current overview and recommendations for the treatment of CAT.

Keywords

venous thromboembolism - cancer - anticoagulation

Full Text

References

References
1 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
2 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
3 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
4 Meyer G, Planquette B. Incidental venous thromboembolism, detected by chance, but still venous thromboembolism. Eur Respir J 2020; 55 (02) 2000028
5 Khorana AA, Rubens D, Francis CW. Screening high-risk cancer patients for VTE: a prospective observational study. Thromb Res 2014; 134 (06) 1205-1207
6 Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AYY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014; 134 (06) 1214-1219
7 Riess H, Kretzschmar A, Heinken A, Mohebbi D, May M, Schellong S. Anticoagulation therapy in cancer patients with thrombosis in the outpatient sector of Germany (The CERTIFICAT Initiative)-German Practice of Anticoagulation Therapy of Cancer Patients with Thrombosis. Hamostaseologie 2022; 42 (03) 166-173
8 Linnemann B, Blank W, Doenst T. et al. Diagnostik und Therapie der tiefen Venenthrombose und Lungenembolie – AWMF-S2k-Leitlinie. Stand: 11.01.2023. Verfügbar unter: https:/register.awmf.org/de/leitlinien/detail/065–002 Zugriff am: 04.08. 2023
9 Linnemann et al. publication in this issue
10 Opitz et al. publication in this issue
11 Carrier M, Lee AYY, Bates SM, Anderson DR, Wells PS. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res 2008; 123 (01) 177-183
12 Klamroth R, Sinn M, Pollich C. et al. Anticoagulation practice in patients with cancer-associated thrombosis: insights from GeCAT, a German Prospective Registry Study. Oncol Res Treat 2022; 45 (04) 178-185
13 Frere C, Farge D, Schrag D, Prata PH, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2022; 15 (01) 69
14 Schrag D, Uno H, Rosovsky R. et al; CANVAS Investigators. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA 2023; 329 (22) 1924-1933
15 Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost 2020; 4 (04) 550-561
16 Mulder FI, Bosch FTM, Young AM. et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020; 136 (12) 1433-1441
17 Klamroth et al. publication in this issue
18 Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol 2018; 132: 169-179
19 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
20 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
21 Peñaloza-Martínez E, Demelo-Rodríguez P, Proietti M. et al. Update on extended treatment for venous thromboembolism. Ann Med 2018; 50 (08) 666-674
22 Carrier M, Abou-Nassar K, Mallick R. et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
23 Khorana AA, Soff GA, Kakkar AK. et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728
24 Larsen TL, Garresori H, Brekke J. et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost 2022; 20 (05) 1166-1181
25 McBane II RD, Loprinzi CL, Ashrani A. et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol 2020; 104 (02) 88-96
26 Samuelson Bannow BT, Lee A, Khorana AA. et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (06) 1246-1249
27 Falanga A, Leader A, Ambaglio C. et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022; 6 (08) e750
28 Mermel LA, Allon M, Bouza E. et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49 (01) 1-45 Dossage error! Correction in Clin Infect Dis. 2010 Apr 1;50(7):1079
29 Kovacs MJ, Kahn SR, Rodger M. et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5 (08) 1650-1653
30 Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial–the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12 (08) 951-955
31 Deitcher SR, Fesen MR, Kiproff PM. et al; Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20 (01) 317-324
32 Mulder FI, Di Nisio M, Ay C. et al. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J 2020; 55 (02) 1901697
33 Wiklund P, Medson K, Elf J. Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death. Thromb Res 2023; Apr; 224: 65-72 . Epub 2023 Feb 21. PMID: 36867992.